glp-1 drug novo nordisk Ozempic is first FDA-approved for kidney disease Novo Nordisk cuts GLP-1 prices
Description
doi: 10.1016/j.appet.2018.05.131
26 Certain GLP-1 agonist drugs have been associated with a significantly increased risk of depression and anxiety, 27 highlighting an emerging need for complimentary therapies to support patients mental and emotional health while undergoing pharmaceutical GLP-1 therapy
They do not contain any of the GLP-1 drugs
Understanding the pricing structure helps identify both reasonable deals and suspicious ones
Saraiva, F
